View Press Releases
-
Creative Enzymes Expands Its Probiotic Portfolio
-
BOC Sciences: Peptides Open New Path toward Osteoporosis Treatment
BOC Sciences declares that some of its peptide products have been proven applicable for osteoporosis treatment, which is a significant contribution to the therapeutic areas.
Nov 1, 2022
-
BOC Sciences Makes Easy Access to Polymerization Tech
Owing to the continuously upgraded synthesis technologies and analytical abilities, BOC Sciences has performed well in the polymer industry, serving the community with a comprehensive product portfolio and valuable technical support.
Nov 1, 2022
-
Rising Prevalence of Isotope Labeling Carbohydrates Drives Innovations at BOC Sciences
BOC Sciences provides global customers with a range of high-quality stable isotope labeling compounds for biomedical research. It recently announced the availability of labeled carbohydrates, arousing an enthusiastic response from the market.
Nov 1, 2022
-
BOC Sciences: ADC Analysis and Characterization Support Development, Registration, and Release
BOC Sciences announces support for antibody-drug conjugate (ADC) development, registration, and release by providing comprehensive analysis and characterization technologies.
Nov 1, 2022
-
Metatranscriptome Analysis Service Is Now Available at CD Genomics
-
Meet CD Genomics at the SITC 37th Annual Meeting
-
Extensive Options for Graphene Quantum Dot Modifications
-
Pretreatment Chemicals Make Electroplating More Efficient
-
BRIM Biotechnology receives FDA agreement on Phase 3 clinical trial design for BRM421, BRIM’s lead candidate for Dry Eye Disease, at End of Phase 2 Meeting
BRIM Biotechnology, Inc. ("BRIM," TPEx 6885) is pleased to announce that it has received agreement from the US Food and Drug Administration (FDA) on the Phase 3 clinical trial design for its lead candidate for Dry Eye Disease (DED), BRM421, at the End of Phase 2 Meeting. BRIM will submit the Phase 3 study protocol to the FDA in Q4 2022.
Oct 31, 2022
-
Proscia Presents Study Results On New Artificial Intelligence That Predicts Diagnostic Concordance For Melanoma
Findings illustrate promise of technology to lower misdiagnosis rate for deadliest form of skin cancer
Oct 31, 2022
-
Creative Biogene Develops Custom Lentivirus Services to Support Stable Cell Line Generation
-
Microbiosci Releases LPS Extraction Service to Support Managing Endotoxins Issues
-
Nanoparticle Development Services for Drug Delivery System Research
-
Creative Biogene Delivers Knockout Mouse Models to Support Gene Editing and Future Studies
-
Acylation Reagents for Gas Chromatography and Other Instrumental Analytical Methods
-
ExoQuali Products and Protocols Released by Creative Bioarray to Easy Exosome Isolation Process
-
Histobiolab Provides Over 150 Fish Probes to Satisfy Precise Biological Research Needs
-
Creative Bioarray Provides 3D Cell Patterning Service Based to Speed up Drug Screening
-
PubHive Upgrades SaaS Platform to MedDRA Version 25.1
Drug safety and pharmacovigilance (DSPV) teams that license access to the PubHive Navigator platform can now access the newest MedDRA version when performing signal evaluation and reporting activities
Oct 31, 2022